Verseon (LSE:VERS) Common Stock : £0.13 Mil (As of Jun. 2019)

View and export this data going back to 2015. Start your Free Trial

What is Verseon Common Stock?

Verseon's quarterly common stock increased from Jun. 2018 (£0.11 Mil) to Dec. 2018 (£0.12 Mil) and increased from Dec. 2018 (£0.12 Mil) to Jun. 2019 (£0.13 Mil).

Verseon's annual common stock declined from Dec. 2016 (£0.12 Mil) to Dec. 2017 (£0.11 Mil) but then increased from Dec. 2017 (£0.11 Mil) to Dec. 2018 (£0.12 Mil).

Verseon Common Stock Historical Data

The historical data trend for Verseon's Common Stock can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Verseon Common Stock Chart

Verseon Annual Data

Trend

Dec11

Dec12

Dec13

Dec14

Dec15

Dec16

Dec17

Dec18

Common Stock

Get a 7-Day Free Trial

9.11

0.10

0.12

0.11

0.12

Verseon Semi-Annual Data
	Dec11	Dec12	Dec13	Jun14	Dec14	Jun15	Dec15	Jun16	Dec16	Jun17	Dec17	Jun18	Dec18	Jun19
Common Stock	Get a 7-Day Free Trial									0.12	0.11	0.11	0.12	0.13

Verseon Common Stock Calculation

Common stock is listed on the Balance Sheet at the par value of the total shares outstanding of a company.

The par value of common stocks is meaningless. It is usually set at an absurdly low number.

Verseon (LSE:VERS) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Verseon Corp (LSE:VERS) » Definitions » Common Stock

Comparable Companies

Traded in Other Exchanges

N/A

Address

47071 Bayside Parkway, Fremont, CA, USA, 94538

Website

http://www.verseon.com

Verseon Corp is a part of the healthcare sector in the United States. It is a technology-based pharmaceutical company with a computer-driven drug discovery platform. The company designs novel drug candidates that are unlikely to be found using conventional methods. It is also engaged in drug discovery programs such as the diabetic macular edema product candidates, which treat the diseases by controlled disruption of the kallikrein kinin cascade.